Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reichert

Showing results (111-120 of 438) with videos related to

Pageof 44
Sort By:
Nature Reviews. Drug Discovery|November 7, 2025
Innovative antibody therapeutic development in China compared with the USA and EuropeSilvia Crescioli, Janice M Reichert
Mabs|June 16, 2012
Marketing approval of mogamulizumab: a triumph for glyco-engineeringAlain Beck, Janice M Reichert
Mabs|December 6, 2018
Antibodies to watch in 2019Hélène Kaplon, Janice M Reichert
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 13, 2001
Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparisonJ M Reichert, E M Healy
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|October 30, 2009
Octreotide: a clinical updateR F Meier, M M Reichert
Nature Reviews. Drug Discovery|March 7, 2006
Anti-infective monoclonal antibodies: perils and promise of developmentJanice M Reichert, Matthew C Dewitz
Health Affairs (Project Hope)|January 1, 1985
Prognosis for the autopsyC M Reichert, V L Kelly
The Journal of Biological Chemistry|March 29, 2000
The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signalingM Reichert, T Müller, W Hunziker
Drug Discovery Today|January 15, 2008
Development trends for new cancer therapeutics and vaccinesJanice M Reichert, Julia B Wenger
Pageof 44

Showing results (111-120 of 438) with videos related to

Sort By:
Pageof 44
Nature Reviews. Drug Discovery|November 7, 2025
Innovative antibody therapeutic development in China compared with the USA and EuropeSilvia Crescioli, Janice M Reichert
Mabs|June 16, 2012
Marketing approval of mogamulizumab: a triumph for glyco-engineeringAlain Beck, Janice M Reichert
Mabs|December 6, 2018
Antibodies to watch in 2019Hélène Kaplon, Janice M Reichert
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 13, 2001
Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparisonJ M Reichert, E M Healy
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|October 30, 2009
Octreotide: a clinical updateR F Meier, M M Reichert
Nature Reviews. Drug Discovery|March 7, 2006
Anti-infective monoclonal antibodies: perils and promise of developmentJanice M Reichert, Matthew C Dewitz
Health Affairs (Project Hope)|January 1, 1985
Prognosis for the autopsyC M Reichert, V L Kelly
The Journal of Biological Chemistry|March 29, 2000
The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells. Evidence for a role of beta-catenin/Tcf/Lef signalingM Reichert, T Müller, W Hunziker
Drug Discovery Today|January 15, 2008
Development trends for new cancer therapeutics and vaccinesJanice M Reichert, Julia B Wenger
Pageof 44